Response of RGC to Optic Nerve Injury
About the Research Project
Program
Award Type
Standard
Award Amount
$30,000
Active Dates
April 01, 2000 - March 31, 2001
Grant ID
G2000031
Summary
Abnormalities in the processes of retinal ganglion cells (RGCs) can lead to cell death and vision loss. One of the signals that may lead to cell death in RGCs is an influx of calcium. Dr. Keirstead has developed a surgical procedure to examine retinal ganglion cells in vivo in an anesthetized mouse. In a previous study funded by NGR, she made progress in developing a method of labeling ganglion cells with a dye that allows her to measure changes in the cells’ calcium concentration. Her current goal is to optimize this method of examining changes in calcium in response to nerve cell damage. The further refinement of this method will allow Dr. Keirstead to directly assess the role of calcium in optic nerve damage, and to test the effects of various drugs on this process.
Related Grants
National Glaucoma Research
Exploring Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Qi Cui, MD, PhD
Current Organization
University of Pennsylvania, Perelman School of Medicine
Exploring Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Qi Cui, MD, PhD
Current Organization
University of Pennsylvania, Perelman School of Medicine
National Glaucoma Research
Measuring the Effects of Visual Stimuli on Retinal Blood Vessels and Flow
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Stuart Gardiner, PhD
Current Organization
Good Samaritan Foundation, Legacy Health System
Measuring the Effects of Visual Stimuli on Retinal Blood Vessels and Flow
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Stuart Gardiner, PhD
Current Organization
Good Samaritan Foundation, Legacy Health System
National Glaucoma Research
Developing New Drugs for Glaucoma
Active Dates
January 01, 2026 - December 31, 2027
Principal Investigator
Pete Williams, PhD
Current Organization
Karolinska Institutet
Developing New Drugs for Glaucoma
Active Dates
January 01, 2026 - December 31, 2027
Principal Investigator
Pete Williams, PhD
Current Organization
Karolinska Institutet